{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:48:06Z","timestamp":1778687286337,"version":"3.51.4"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cytomegalovirus (CMV) is a major opportunistic pathogen in recipients of solid organ transplantation. Maribavir, a pUL97 protein kinase inhibitor, was approved for the treatment of refractory post-transplant CMV infection in the US in 2021. However, it is rarely used in pediatric patients worldwide. Here, we report the case of a Chinese boy with Schimke\u2019s immune-osseous dysplasia (SIOD) who developed refractory CMV infection after a renal transplantation. An 11-year-old boy was hospitalized with recurrent abdominal and testicular pain 50 days after renal transplantation. Diagnoses included urinary tract infection, epididymitis, CMV viremia, stage 2 chronic kidney disease, and SIOD. After five days of treatment, his pain improved, but he developed persistent fever and shortness of breath. Blood CMV levels rose to 1.64 \u00d7 10<jats:sup>5<\/jats:sup> copies\/ml after one month of ganciclovir treatment. Significant bone marrow suppression was observed after combined treatment with foscarnet. Anti-rejection treatment was discontinued due to compromised immune function. On day 40, maribavir was initiated with parental consent, resulting in undetectable CMV copies within four days. The patient\u2019s clinical status and bone marrow suppression had improved. Continuing maribavir for two weeks led to the disappearance of CMV viremia, no bone marrow suppression, and normal liver and kidney functions. This case demonstrates the successful short-term use of maribavir in the treatment of refractory CMV infection in an immune-deficient child after renal transplantation. Further studies are required to explore the efficacy and safety of maribavir in pediatric patients.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1521763","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T05:32:26Z","timestamp":1744003946000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Maribavir for refractory cytomegalovirus viremia after renal transplantation in a child with Schimke\u2019s immune-osseous dysplasia"],"prefix":"10.3389","volume":"16","author":[{"given":"Jia-Shuan","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ping","family":"Rong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Yun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long-Shan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu-Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Hui","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/qco.0000000000000107","article-title":"Cytomegalovirus","volume":"27","author":"Griffiths","year":"2014","journal-title":"Curr Opin Infect Dis Dec"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transplant. May"},{"key":"B3","doi-asserted-by":"publisher","first-page":"Cd003774","DOI":"10.1002\/14651858.CD003774.pub2","article-title":"Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients","author":"Hodson","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0657-y","article-title":"Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor","volume":"92","author":"Asakura","year":"2010","journal-title":"Int J Hematol Sep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/1120009x.2021.1915074","article-title":"Relationship between renal dysfunction and electrolyte abnormalities in hematopoietic stem cell transplant patients treated with foscarnet","volume":"33","author":"Ota","year":"2021","journal-title":"J Chemother Dec"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant. Sep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13521","article-title":"Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection","volume":"23","author":"Mehta Steinke","year":"2021","journal-title":"Transpl Infect Dis Jun"},{"key":"B8","article-title":"FDA approves first treatment for common type of post-transplant infection that is resistant to other drugs","year":"2021"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ng821","article-title":"Mutant chromatin remodeling protein SMARCAL1 causes Schimke immuno-osseous dysplasia","volume":"30","author":"Boerkoel","year":"2002","journal-title":"Nat Genet Feb"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s004310050001","article-title":"Manifestations and treatment of Schimke immuno-osseous dysplasia: 14 new cases and a review of the literature","volume":"159","author":"Boerkoel","year":"2000","journal-title":"Eur J Pediatr"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180926","article-title":"Low renal but high extrarenal phenotype variability in Schimke immuno-osseous dysplasia","volume":"12","author":"Lipska-Zi\u0119tkiewicz","year":"2017","journal-title":"PloS One"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.979722","article-title":"T-cell receptor signaling in Schimke immuno-osseous dysplasia is SMARCAL1-independent","volume":"13","author":"Marin","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1086\/514041","article-title":"High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes","volume":"176","author":"Smith","year":"1997","journal-title":"J Infect Dis Jul"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the transplant associated virus infections forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000148239.00384.f0","article-title":"Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients","volume":"79","author":"Rowshani","year":"2005","journal-title":"Transplantation"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2217\/fvl.12.8","article-title":"The immune response to human CMV","volume":"7","author":"La Rosa","year":"2012","journal-title":"Future Virol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000001095","article-title":"The immunology of posttransplant CMV infection: potential effect of CMV immunoglobulins on distinct components of the immune response to CMV","author":"Carbone","year":"2016","journal-title":"Transplantation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e13977","DOI":"10.1111\/tid.13977","article-title":"Cytomegalovirus in the transplant setting: Where are we now and what happens next? A report from the International CMV Symposium 2021","volume":"24","author":"Kotton","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ph15070797","article-title":"Anti-cytomegalovirus therapy: whether and when to initiate, those are the questions","author":"Aoyama","year":"2022","journal-title":"Pharm (Basel)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/0140-6736(90)92253-e","article-title":"Foscarnet and crystals in glomerular capillary lumens","volume":"336","author":"Beaufils","year":"1990","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/2042-4280-1-4","article-title":"The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein","volume":"1","author":"Shannon-Lowe","year":"2010","journal-title":"Herpesviridae"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.615","article-title":"Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir","volume":"19","author":"Prichard","year":"2009","journal-title":"Rev Med Virol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2165\/00003495-199448020-00007","article-title":"A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections","volume":"48","author":"Wagstaff","year":"1994","journal-title":"Drugs"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2024.1394006","article-title":"Case Report: Approaches for managing resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplantation recipients","volume":"12","author":"Song","year":"2024","journal-title":"Front Pediatr"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/mph.0000000000002841","article-title":"Use of maribavir for multidrug resistant cytomegaloviremia in a pediatric oncology patient","volume":"46","author":"Fisher","year":"2024","journal-title":"J Pediatr Hematol Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-330","article-title":"Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient","volume":"13","author":"Schubert","year":"2013","journal-title":"BMC Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation","volume":"381","author":"Maertens","year":"2019","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/qco.0000000000000170","article-title":"Approach to drug-resistant cytomegalovirus in transplant recipients","volume":"28","author":"Chou","year":"2015","journal-title":"Curr Opin Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02405-21","article-title":"New perspectives on antimicrobial agents: maribavir","volume":"66","author":"Halpern-Cohen","year":"2022","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1521763\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T05:32:28Z","timestamp":1744003948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1521763\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2025.1521763"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1521763","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"article-number":"1521763"}}